Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 10 of 857 for:    Advanced | Neuroendocrine Tumors

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01381822
Recruitment Status : Unknown
Verified April 2014 by Threshold Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : June 27, 2011
Last Update Posted : April 21, 2014
Information provided by (Responsible Party):
Threshold Pharmaceuticals

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Unknown
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : June 2014
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 July 14, 2017
(Canceled - Date Unknown)
December 19, 2017
September 5, 2018